-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2041 Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs

Program: Oral and Poster Abstracts
Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Combination therapy, Treatment Considerations
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Guo-Ling Wang1,2*, Ting Wang1,2*, Jing-Li Han1*, Li-Xin Wu1,2*, Xuan-Zhong Chen1,2*, Zhuo-Yu An1*, Chen-Cong Wang1*, Peng Zhao1*, Lu-Lu Wang1*, Mengtong Zang, MS1*, Wei Zheng3*, Hai-Xia Fu1*, Jia Feng4*, Hong-Yu Zhang4* and Xiaohui Zhang1

1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
2Department of Hematology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
3Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China
4Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China

Introduction:

Patients with refractory or relapsed T-cell acute lymphoblastic leukemia (R/R-T-ALL) face a dire prognosis. Even with salvage hematopoietic stem cell transplantation (HSCT), survival rates seldom exceed 30%, primarily due to disease relapse and transplant-related morbidity. This highlights the critical need for more effective and less toxic preconditioning regimens to improve HSCT outcomes. Recent multicenter studies have indicated that CD7 CAR-T-cell therapy can induce complete remission in approximately 90% of R/R T-ALL patients within one month of infusion. However, the long-term efficacy of CAR-T-cell therapy is compromised by antigen-negative relapse and severe infections, which often require additional bone marrow transplantation for consolidation. Despite these challenges, emerging clinical data support the integration of donor-derived CD7 CAR-T-cell therapy with HSCT, suggesting the viability of CAR-T-cell therapy as a preconditioning regimen. This study aimed to develop and evaluate a novel dual-target CD5-CD7 CAR-T-cell therapy as a preconditioning strategy for epitope-edited allogeneic HSCT, with the goal of establishing a novel treatment for R/R T-ALL.

Methods:

Leveraging established methodologies, we engineered Tan5-7 CAR-T cells that concurrently target the CD5 and CD7 antigens. We employed a base editor (BE) to modify the CD5- and CD7-binding epitopes in HSCs. In vivo experiments involved injecting T-ALL tumor cells intravenously via the tail vein, with subsequent in vivo imaging and flow cytometry performed to confirm tumor cell engraftment. The mice were randomly divided into groups: the experimental group underwent preconditioning with fludarabine and cyclophosphamide for three consecutive days before receiving Tan5-7 CAR-T-cell infusion; one control group received the same FC preconditioning followed by an infusion of control T cells (Tcon+HSCT group); and the other control group underwent a standard HSCT preconditioning regimen followed by allogeneic bone marrow transplantation (standard HSCT group). We monitored the tumor load, CAR-T-cell proliferation, and spectrum of peripheral blood cells weekly after transplantation. The mice were also observed for indicators such as weight, temperature, hair loss, diarrhea, and kyphosis to assess graft-versus-host disease (GVHD), infections, and other adverse events, along with survival rates.

Results:

Tan5-7 CAR-T cells effectively eliminated T-ALL tumor cells both in vivo and in vitro, and depleted T, NK, and partial B cells from normal donor PBMCs. Unlike the Tcon+HSCT group, where HSCs failed to engraft, the Tan5-7 CAR-T-cell infusion enabled successful allogeneic HSC engraftment without pretransplant conditioning, achieving engraftment efficiencies comparable to those of standard conditioning regimens, predominantly resulting in complete chimerism. Post-engraftment, there were no significant differences in the counts in myeloid cells, megakaryocytes, or platelets between the experimental and control groups. Compared with the standard HSCT group, the Tan5-7 CAR-T + HSCT group presented significantly lower counts of T, NK, and B cells post-transplant and a lower incidence of GVHD but a higher rate of infectious mortality.

We edited single amino acid mutations in CD5/CD7 antigen-binding epitopes in HSCT, enabling BE-T/NK/B cells to be resistant to Tan5-7 CAR recognition. Preliminary data indicated that the Tan5-7 CAR-T + BE-HSCT group presented significantly greater post-transplant T, NK, and B-cell counts compared with the Tan5-7 CAR-T + HSCT group, without a corresponding increase in short-term GVHD incidence. Additionally, the levels of engrafted T-cell counts and TCR clonal diversity appeared to be negatively correlated with GVHD occurrence, whereas T cells differentiated from engrafted HSCs did not significantly increase the risk of GVHD.

Conclusions:

Tan5-7 CAR-T-cell therapy effectively eliminates tumor cells and selectively depletes various immune effector cells, offering a viable alternative to traditional conditioning regimens for HSCT. Antigen epitope-edited HSCT restores peripheral blood immune cell counts without significantly increasing adverse reactions such as GVHD. This dual-target CAR-T-cell bridging strategy with antigen epitope-edited HSCT represents a promising therapeutic option for patients with R/R-T-ALL.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH